Differential in vitro activity of the DNA topoisomerase inhibitor idarubicin against Trypanosoma rangeli and Trypanosoma cruzi

AUTOR(ES)

Jobe, Momodou, Anwuzia-Iwegbu, Charles, Banful, Ama, Bosier, Emma, Iqbal, Mubeen, Jones, Kelly, Lecutier, Suzanne J, Lepper, Kasimir, Redmond, Matt, Ross-Parker, Andrew, Ward, Emily, Wernham, Paul, Whidden, Eleanor M, Tyler, Kevin M, Steverding, Dietmar

FONTE

Mem. Inst. Oswaldo Cruz

DATA DE PUBLICAÇÃO

2012-11

RESUMO

In this study the effect of eight DNA topoisomerase inhibitors on the growth Trypanosoma rangeli epimastigotes in cell culture was investigated. Among the eight compounds tested, idarubicin was the only compound that displayed promising trypanocidal activity with a half-maximal growth inhibition (GI50) value in the sub-micromolar range. Fluorescence-activated cell sorting analysis showed a reduction in DNA content in T. rangeli epimastigotes when treated with idarubicin. In contrast to T. rangeli, against Trypanosoma cruzi epimastigotes idarubicin was much less effective exhibiting a GI50 value in the mid-micromolar range. This result indicates that idarubicin displays differential toxic effects in T. rangeli and T. cruzi. Compared with African trypanosomes, it seems that American trypanosomes are generally less susceptible to DNA topoisomerase inhibitors.

Documentos Relacionados

• In vitro activity of Etanidazole against the protozoan parasite Trypanosoma cruzi
• In vitro evaluation of the activity of aromatic nitrocompounds against Trypanosoma cruzi
• In vitro activity of thienyl-2-nitropropene compounds against Trypanosoma cruzi
• Vaccination with epimastigotes of different strains of Trypanosoma rangeli protects mice against Trypanosoma cruzi infection
• Vaccination of dogs with Trypanosoma rangeli induces antibodies against Trypanosoma cruzi in a rural area of Córdoba, Argentina